Journal Mobile Options
Table of Contents
Vol. 128, No. 4, 2002
Issue release date: August 2002
Int Arch Allergy Immunol 2002;128:315–324
(DOI:10.1159/000063860)

Monoclonal Antibodies against the CεmX Domain of Human Membrane-Bound IgE and Their Potential Use for Targeting IgE-Expressing B Cells

Chen H.Y. · Liu F.-T. · Hou C.M.H. · Huang J.S.W. · Sharma B.B. · Chang T.W.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: IgE mediates immediate-type hypersensitivity reactions responsible for various allergic symptoms. It is secreted by IgE-producing plasma cells, which differentiate from B cells expressing membrane-bound IgE (mIgE) on their surface. The ε-chain of human mIgE contains a membrane-anchoring peptide and an extra 52-amino-acid (a.a.)-long domain (referred to as CεmX) between the membrane anchor and the CH4 domain. Objective: The study was designed to evaluate the effects of CεmX-specific monoclonal antibodies (mAbs) to target IgE-expressing B cells and decrease IgE production. Methods: A CεmX-containing IgG1.Fc fusion protein was produced in CHO cells and used to immunize mice; five hybridoma clones secreting CεmX-specific mAbs were obtained. Results: Characterization of the mAbs using ELISA, immunoprecipitation, and immunoblotting methods showed that they could bind to both native and denatured forms of CεmX. The mAbs exhibited mutual inhibition of binding to mIgE. Epitope mapping using synthetic peptides revealed that all five mAbs recognize the same epitope, RADWPGPP, located near the C-terminus of CεmX . Binding of one of the mAbs to mIgE on SKO-007 cells induced the cross-linking of mIgE molecules on the cell surface, resulting in their patching and capping. In vitro functional analysis revealed that mAbs are able to cause complement-mediated cytotoxicity on transfectants expressing the Fc portion of mIgE. Conclusion: We have prepared several human mIgE-specific mAbs. The potential of the mAbs on targeting mIgE+ B cells was demonstrated by CDC analysis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Lam KP, Kuhn R, Rajewsky K: In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997;90:1073–1083.

    External Resources

  2. Achatz G, Nitschke L, Lamers MC: Effect of transmembrane and cytoplasmic domains of IgE on the IgE response. Science 1997;276:409–411.
  3. Kaisho T, Schwenk F, Rajewsky K: The roles of gamma 1 heavy chain membrane expression and cytoplasmic tail in IgG1 responses. Science 1997;276:412–415.
  4. Tarlinton D: Antigen presentation by memory B cells: The sting is in the tail. Science 1997;276:374–375.
  5. Coffman RL, Lebman DA, Rothman P: Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 1993;54:229–270.
  6. Matsumoto M, Lo SF, Carruthers CJ, Min J, Mariathasan S, Huang G, Plas DR, Martin SM, Geha RS, Nahm MH, Chaplin DD: Affinity maturation without germinal centres in lymphotoxin-alpha-deficient mice. Nature 1996;382:462–466.
  7. Berek C, Berger A, Apel M: Maturation of the immune response in germinal centers. Cell 1991;67:1121–1129.
  8. Vitetta ES, Berton MT, Burger C, Kepron M, Lee WT, Yin XM: Memory B and T cells. Annu Rev Immunol 1991;9:193–217.
  9. Chang TW, Davis FM, Sun NC, Sun CR, MacGlashan DW, Hamilton RG: Monoclonal antibodies specific for human IgE-producing B cells: A potential therapeutic for IgE-mediated allergic diseases. Biotechnology (NY) 1990;8:122–126.
  10. Davis FM, Gossett LA, Chang TW: An epitope on membrane-bound but not secreted IgE: Implications in isotype-specific regulation. Biotechnology (NY) 1991;9:53–56.
  11. Davis FM, Gossett LA, Pinkston KL, Liou RS, Sun LK, Kim YW, Chang NT, Chang TW, Wagner K, Bews J, Brinkmann V, Towbin H, Subramanian N, Heusser C: Can anti-IgE be used to treat allergy? Springer Semin Immunopathol 1993;15:51–73.

    External Resources

  12. Chang TW: The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000;18:157–162.
  13. Ishizaka K: Regulation of the IgE antibody response. Int Arch Allergy Appl Immunol 1989;88:8–13.

    External Resources

  14. Tanaka H, Nagai H, Maeda Y: Effect of anti-IL-4 and anti-IL-5 antibodies on allergic airway hyperresponsiveness in mice. Life Sci 1998;62:PL169–174.
  15. Wright JD, Lim C: Prediction of an anti-IgE binding site on IgE. Protein Eng 1998;11:421–427.

    External Resources

  16. Fahy JV: Reducing IgE levels as a strategy for the treatment of asthma. Clin Exp Allergy 2000;30(suppl 1):16–21.
  17. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Cioppa GD, Sandstrom T: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253–259.
  18. Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ: Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999;341:1966–1973.
  19. Demoly P, Bousquet J: Anti-IgE therapy for asthma. Am J Respir Crit Care Med 1997;155:1825–1827.
  20. MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM: Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438–1445.
  21. Yamaguchi M, Sayama K, Yano K, Lantz CS, Noben-Trauth N, Ra C, Costa JJ, Galli SJ: IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: Synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J Immunol 1999;162:5455–5465.
  22. Ishida N, Ueda S, Hayashida H, Miyata T, Honjo T: The nucleotide sequence of the mouse immunoglobulin epsilon gene: Comparison with the human epsilon gene sequence. EMBO J 1982;1:1117–1123.
  23. Peng C, Davis FM, Sun LK, Liou RS, Kim YW, Chang TW: A new isoform of human membrane-bound IgE. J Immunol 1992;148:129–136.

    External Resources

  24. Saxon A, Zhang K, Max EE: Human epsilon mRNAs using membrane sequence encode for two membrane forms of IgE and a novel second secreted IgE. Trans Assoc Am Physicians 1992;105:93–99.
  25. Batista FD, Efremov DG, Burrone OR: Characterization and expression of alternatively spliced IgE heavy chain transcripts produced by peripheral blood lymphocytes. J Immunol 1995;154:209–218.

    External Resources

  26. Diaz-Sanchez D, Zhang K, Nutman TB, Saxon A: Differential regulation of alternative 3′-splicing of epsilon messenger RNA variants. J Immunol 1995;155:1930–1941.

    External Resources

  27. Nilsson K, Bennich H, Johansson SG, Ponten J: Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol 1970;7:477–489.

    External Resources

  28. Gefter ML, Margulies DH, Scharff MD: A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet 1977;3:231–236.

    External Resources

  29. Liu FT, Bohn JW, Ferry EL, Yamamoto H, Molinaro CA, Sherman LA, Klinman NR, Katz DH: Monoclonal dinitrophenyl-specific murine IgE antibody: Preparation, isolation, and characterization. J Immunol 1980;124:2728–2737.
  30. Sheu JJC, Huang J, Chang TW: Inducing specific reactivity against B cells in mice by immunizing with an Fc fusion protein containing self-Ig β. Cancer Immunol Immunother 2002;51:145–152.
  31. Huang J, Sheu JJC, Wu SCS, Chang TW: Down-regulation of B cells by immunization with a fusion protein of a self CD20 peptide and a foreign IgG.Fc fragment. Immunol Lett 2002;81:49–58.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50